Ryvu Therapeutics SA
Research Ryvu Therapeutics SA (RVU) on Bullrun: market cap PLN 323.68M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRVU
- ExchangeWAR
- CountryPoland
- SectorHealthcare
- IndustryBiotechnology
- CurrencyPLN
- Market capPLN 323.68M
- Financial periodQ4 2025
- RevenuePLN 18.00M
- Net income-PLN 17.59M
- Free cash flow-PLN 32.91M
- Gross margin77.3%
Valuation Snapshot
latest market cap is PLN 323.68M.
About Ryvu Therapeutics SA
Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company's lead candidate, Romaciclib (RVU120), is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myelofibrosis.
Frequently asked questions
What is Ryvu Therapeutics SA's market cap?
Ryvu Therapeutics SA's market capitalization is PLN 323.68M.
What does Ryvu Therapeutics SA do?
Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally.